# Acrivon Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Acrivon Therapeutics, Inc.). ## Overview Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing precision oncology therapies using its proprietary AP3 platform. The company’s lead programs are ACR-368 and ACR-2316, and it also develops drug-tailored OncoSignature tests intended to match patients to the right therapy. Acrivon has not yet generated product revenue and is still funding research, clinical development, manufacturing scale-up, and regulatory preparation. Its business model is centered on advancing drug candidates through trials, then seeking approvals and, if successful, commercializing directly or through partnerships. ## Products & services • ACR-368 clinical-stage oncology candidate • ACR-2316 clinical-stage oncology candidate • ACR-368 OncoSignature precision medicine test • AP3 drug discovery and optimization platform • Preclinical drug discovery programs • cGMP manufacturing for clinical trial materials - **Clinical-stage drug candidates** (0%) — Small-molecule oncology assets in human trials, including ACR-368 and ACR-2316. - **Precision medicine diagnostics** (0%) — OncoSignature tests designed to identify patients most likely to respond to Acrivon’s therapies. - **Discovery platform** (0%) — The AP3 platform used to optimize compounds in intact cells and support pipeline generation. - **Preclinical pipeline** (0%) — Earlier-stage drug discovery and validation programs that may become future clinical assets. - **Manufacturing and development operations** (0%) — cGMP process development, clinical supply manufacturing, and scale-up activities for candidates. - ACR-368, a clinical-stage oncology drug candidate - ACR-2316, a clinical-stage internally discovered drug candidate - ACR-368 OncoSignature, a drug-tailored precision medicine test - AP3 precision medicine platform for drug discovery and optimization - Preclinical and discovery-stage oncology programs - cGMP manufacturing and clinical trial material supply ## Customers Acrivon does not currently sell approved medicines, so its near-term “customers” are primarily clinical trial sites, investigators, and contract research/manufacturing partners that support development. In the future, if its candidates are approved, the company would sell to oncology patients through hospitals, cancer centers, and specialty prescribers, potentially with reimbursement from payers. The OncoSignature test also implies a companion-diagnostic use case where clinicians and treatment centers would use the assay to guide patient selection. The company may also pursue collaboration partners or licensing counterparties that provide upfront fees, milestones, or R&D reimbursements before commercial launch. - **Clinical development partners** (primary) — CROs, trial sites, and manufacturing partners that execute studies and produce clinical supply for ACR-368, ACR-2316, and related programs. - **Future oncology prescribers** (primary) — Oncologists and cancer centers that would prescribe approved products if Acrivon reaches commercialization. - **Payers and reimbursement bodies** (secondary) — Insurers and health systems that would influence uptake by deciding coverage and reimbursement for approved therapies. - **Collaboration and licensing partners** (secondary) — Biopharma partners that may provide upfront fees, milestones, or R&D funding in exchange for rights or access. - **Diagnostic users** (emerging) — Clinicians and treatment centers that would use the OncoSignature test to identify likely responders. - Clinical trial investigators and sites running ACR-368 and ACR-2316 studies - CROs, CMOs, and other development partners supporting trials and manufacturing - Oncology clinicians and cancer centers that would use approved therapies - Payers and reimbursement systems that would determine access after approval - Potential pharma collaborators or licensees for non-dilutive funding ## Geography Acrivon is a U.S.-based company and its reporting emphasizes operations and funding needs in the United States, where its clinical development, regulatory strategy, and public-company obligations are centered. The company states that it may seek regulatory approvals in the United States and other jurisdictions, which means future commercialization could become multi-region. Its current exposure is therefore driven more by U.S. clinical, regulatory, and capital-market conditions than by international sales. The reports also note geopolitical disruption risk, including the Russia-Ukraine war and Middle East conflict, which can affect trial execution, supply chains, and operating continuity. - Headquartered in the United States - Clinical and regulatory execution is primarily U.S.-centric today - Future approvals may be pursued in the United States and other jurisdictions - No product revenue geography is disclosed because the company has no sales - Geopolitical events can disrupt trials, supply, and operations ## Strategy Acrivon’s strategy is to advance ACR-368 and ACR-2316 through clinical development while continuing to build a broader pipeline from its AP3 platform. The company is also investing in drug-tailored OncoSignature tests to improve patient selection and potentially strengthen the clinical and commercial profile of its therapies. A second priority is to mature manufacturing, regulatory, and commercial infrastructure so it can support approval and launch if a candidate succeeds. Management also highlights the option to use collaborations, licensing, or in-licenses/acquisitions to extend the pipeline and reduce dependence on any single asset. - **Clinical advancement of lead assets** (short-term) — Clinical proof-of-concept is the main value driver because the company has no approved products or revenue. - **Platform-driven pipeline expansion** (medium-term) — AP3-based discovery can create follow-on assets and reduce dependence on a single program. - **Commercial and manufacturing readiness** (medium-term) — If a candidate is approved, the company must be able to supply, market, and distribute product. - **Capital and partnership flexibility** (short-term) — The company expects to need additional funding and may use collaborations to extend runway and reduce dilution. - Advance ACR-368 and ACR-2316 through ongoing clinical trials - Use AP3 to discover and optimize additional oncology candidates - Develop OncoSignature tests to improve patient selection and response rates - Build cGMP manufacturing and commercial readiness ahead of approval - Pursue collaborations or licensing to add non-dilutive funding and assets - Maintain and defend intellectual property around platform and programs ## Risks Acrivon is a pre-revenue biotech with no approved products, so its core risk is that clinical candidates may fail, be delayed, or never reach commercialization. The company expects substantial losses for several years and may need additional capital, which creates dilution and financing risk if markets are unfavorable. Its operations also depend on trial execution, manufacturing capacity, regulatory review, and intellectual property protection, all of which are uncertain and can materially affect value. Broader industry risks include competition from other oncology platforms, changing regulatory standards, reimbursement hurdles, and geopolitical or public-health disruptions that can slow enrollment or supply. - **Clinical development failure** [critical] — The company’s value depends on ACR-368, ACR-2316, and future candidates proving safe and effective in trials. - **Financing and dilution risk** [high] — Acrivon expects to burn cash for years and may need equity, debt, or collaboration funding before commercialization. - **Manufacturing and supply risk** [high] — Clinical and future commercial supply depends on cGMP process development and third-party manufacturing capacity. - **Regulatory approval risk** [high] — Even successful trials do not guarantee approval, and post-marketing studies or jurisdiction-specific requirements may add cost and delay. - **Intellectual property risk** [medium] — The company relies on patents, licenses, and know-how to protect its platform and candidates from competitors. - **Geopolitical and trial disruption risk** [medium] — Management explicitly cites public-health emergencies and geopolitical events as potential causes of trial and operational disruption. - Clinical failure or delay for ACR-368 and ACR-2316 - No product revenue and continued operating losses - Need for additional capital and potential shareholder dilution - Manufacturing scale-up and supply-chain execution risk - Regulatory approval uncertainty in the U.S. and abroad - Intellectual property disputes or inability to protect platform assets - Trial disruption from public health or geopolitical events ## Accounting Acrivon’s accounting is dominated by judgment-heavy biotech items rather than revenue recognition, because it has not generated product sales. Research and development costs are expensed as incurred, so quarterly results can swing materially with trial activity, manufacturing runs, headcount growth, and external CRO/CMO spending. The company also relies on estimates around stock-based compensation, license-related obligations, and the valuation of cash, cash equivalents, and investments, all of which can affect reported losses and balance-sheet presentation. Because it is an emerging growth company, it can defer adoption of some accounting standards, which may reduce comparability with larger public biopharma peers. - **Research and development expense timing** — High quarter-to-quarter volatility in operating results - **Stock-based compensation** — Reported losses and operating expense mix - **License and collaboration obligations** — Future expense and cash outflow uncertainty - **Cash runway and going-concern style analysis** — Liquidity and financing analysis - No product revenue yet, so reported results are driven by expense recognition - R&D is expensed as incurred, making trial timing a major earnings driver - Clinical manufacturing and CRO/CMO costs flow through operating expenses - Stock-based compensation affects personnel-related R&D and G&A costs - License and collaboration obligations may create future milestone expense - Emerging growth company status can affect comparability of accounting standards --- *Last updated: 2026-08-11T04:46:19.398917+00:00*